Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Edward Shannon, Robert Noveck, Felipe Sandoval & Burde Kamath. (2008) Thalidomide Suppressed IL-1β While Enhancing TNF-α and IL-10, When Cells in Whole Blood were Stimulated with Lipopolysaccharide. Immunopharmacology and Immunotoxicology 30:3, pages 447-457.
Read now
Read now
Azeb Tadesse, Markos Abebe, Elizabeth Bizuneh, Wondwossen Mulugeta, Abraham Aseffa & E.J. Shannon. (2006) Effect of Thalidomide on the Expression of TNF-α m-RNA and Synthesis of TNF-α in Cells from Leprosy Patients with Reversal Reaction. Immunopharmacology and Immunotoxicology 28:3, pages 431-441.
Read now
Read now
Bruce C Baguley & William R Wilson. (2002) Potential of DMXAA combination therapy for solid tumors. Expert Review of Anticancer Therapy 2:5, pages 593-603.
Read now
Read now
A. Aseffa, M. A. Dietrich & E. J. Shannon. (1997) Effect of Thalidomide on Apoptosis of Lymphocytes and Neutrophils. Immunopharmacology and Immunotoxicology 19:3, pages 313-326.
Read now
Read now
Michael P Seed. (1996) Section Review Oncologic, Endocrine & Metabolic: Angiogenesis inhibition as a drug target for disease: an update. Expert Opinion on Investigational Drugs 5:12, pages 1617-1637.
Read now
Read now
Articles from other publishers (34)
Xiang ZhangWen-Shen LuXiao-Ming Qin. (2020) Cytokines/Chemokines: Novel Biomarkers Associated with Severe Cutaneous Adverse Reactions. Journal of Interferon & Cytokine Research 40:4, pages 172-181.
Crossref
Crossref
Xiubao Chang, Yuanxiao Zhu, Changxin Shi & A. Keith Stewart. (2014) Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochimica et Biophysica Sinica 46:3, pages 240-253.
Crossref
Crossref
Renana Baratz, David Tweedie, Vardit Rubovitch, Weiming Luo, Jeong Seon Yoon, Barry J. Hoffer, Nigel H. Greig & Chaim G. Pick. (2011) Tumor necrosis factor-α synthesis inhibitor, 3,6′-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. Journal of Neurochemistry 118:6, pages 1032-1042.
Crossref
Crossref
Anna Israyelyan, Edward John Shannon, Abolghasem Baghian, Michael T. Kearney & Konstantin G. Kousoulas. (2009) Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemotherapy and Pharmacology 64:6, pages 1201-1210.
Crossref
Crossref
David Tweedie, Weiming Luo, Ryan G. Short, Arnold Brossi, Harold W. Holloway, Yazhou Li, Qian-sheng Yu & Nigel H. Greig. (2009) A cellular model of inflammation for identifying TNF-α synthesis inhibitors. Journal of Neuroscience Methods 183:2, pages 182-187.
Crossref
Crossref
K. Hyakkoku, Y. Nakajima, H. Izuta, M. Shimazawa, T. Yamamoto, N. Shibata & H. Hara. (2009) Thalidomide protects against ischemic neuronal damage induced by focal cerebral ischemia in mice. Neuroscience 159:2, pages 760-769.
Crossref
Crossref
Cindy H. Chau, William Dahut & William D. Figg. 2008. Angiogenesis. Angiogenesis
387
394
.
Edward Shannon, Robert Noveck, Felipe Sandoval, Burde Kamath & Michael Kearney. (2007) Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. Translational Research 150:5, pages 275-280.
Crossref
Crossref
S M McHUGH & T L ROWLAND. (1997) Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-α) inhibition suggest drugs capable of selective gene regulation. Clinical and Experimental Immunology 110:2, pages 151-154.
Crossref
Crossref
A. James Hanje, Jennifer L Shamp, Fred B Thomas & Greg M Meis. (2006) Thalidomide-Induced Severe Hepatotoxicity. Pharmacotherapy 26:7, pages 1018-1022.
Crossref
Crossref
D. M. Scollard, L. B. Adams, T. P. Gillis, J. L. Krahenbuhl, R. W. Truman & D. L. Williams. (2006) The Continuing Challenges of Leprosy. Clinical Microbiology Reviews 19:2, pages 338-381.
Crossref
Crossref
K. Varma & A.Y. Finlay. (2006) Exacerbation of psoriasis by thalidomide in a patient with erythema multiforme. British Journal of Dermatology 154:4, pages 789-790.
Crossref
Crossref
X. Leleu, J.B. Micol, R. Guieze, C. Berthon, F. Kuhnovsky, L. Terriou, A.S. Moreau, I. Yakoub-Agha, F. Bauters & T. Facon. (2005) Thalidomide : mécanismes d'action et indications en hématologie. La Revue de Médecine Interne 26:2, pages 119-127.
Crossref
Crossref
A. Tadesse & E. J. Shannon. (2005)
Effects of Thalidomide on Intracellular
Mycobacterium leprae
in Normal and Activated Macrophages
. Clinical and Vaccine Immunology 12:1, pages 130-134.
Crossref
Crossref
J N Gordon & P M Goggin. (2003) Thalidomide and its derivatives: emerging from the wilderness. Postgraduate Medical Journal 79:929, pages 127-132.
Crossref
Crossref
Steve K. Teo, Ken E. Resztak, Michael A. Scheffler, Karin A. Kook, Jerry B. Zeldis, David I. Stirling & Steve D. Thomas. (2002) Thalidomide in the treatment of leprosy. Microbes and Infection 4:11, pages 1193-1202.
Crossref
Crossref
Edward J Shannon & Felipe G Sandoval. (2002) Thalidomide can costimulate or suppress CD4+ cells' ability to incorporate [H3]-thymidine—dependence on the primary stimulant. International Immunopharmacology 2:8, pages 1143-1153.
Crossref
Crossref
Shufeng Zhou, Philip Kestell, Malcolm D. Tingle & James W. Paxton. (2002) Thalidomide in Cancer Treatment. Drugs & Aging 19:2, pages 85-100.
Crossref
Crossref
Bernard Combe. (2001) Thalidomide: new indications?. Joint Bone Spine 68:6, pages 582-587.
Crossref
Crossref
Bernard Combe. (2001) Le thalidomide : vers de nouvelles indications ?. Revue du Rhumatisme 68:10-11, pages 951-957.
Crossref
Crossref
Christian Meierhofer, Stefan Dunzendorfer & Christian J. Wiedermann. (2001) Theoretical Basis for the Activity of Thalidomide. BioDrugs 15:10, pages 681-703.
Crossref
Crossref
Todd E. Clark, Norma Edom, Janice Larson & Laura J. Lindsey. (2001) Thalomid?? (Thalidomide) Capsules. Drug Safety 24:2, pages 87-117.
Crossref
Crossref
B Grosbois & C Duguet. (2001) Thalidomide : le renouveau. La Revue de Médecine Interne 22:1, pages 5-7.
Crossref
Crossref
E Shannon, A Aseffa, G Pankey, F Sandoval & B Lutz. (2000) Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood. Immunopharmacology 46:2, pages 175-179.
Crossref
Crossref
Z Cao, W R Joseph, W L Browne, K G Mountjoy, B D Palmer, B C Baguley & L-M Ching. (1999) Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. British Journal of Cancer 80:5-6, pages 716-723.
Crossref
Crossref
Mauricio Goihman‐Yahr. (2001) Thalidomide as an inhibitor of tumor necrosis factor‐α production: a word of caution. International Journal of Dermatology 38:1, pages 76-77.
Crossref
Crossref
Reinhard Neubert & Diether Neubert. 1999. Toxicology. Toxicology
371
437
.
MEIKE WÖRDEMANN, JOACHIM FANDREY & WOLFGANG JELKMANN. (1998) Tumor Necrosis Factor-α Production by Human Hepatoma Cell Lines Is Resistant to Drugs That Are Inhibitory to Macrophages. Journal of Interferon & Cytokine Research 18:12, pages 1069-1075.
Crossref
Crossref
Pierre Wolkenstein, Jacques Latarjet, Jean-Claude Roujeau, Corinne Duguet, Sylvie Boudeau, Loöc Vaillant, Michel Maignan, Marie-Hélène Schuhmacher, Brigitte Milpied, Alain Pilorget, Hélène Bocquet, Christian Brun-Buisson & Jean Revuz. (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. The Lancet 352:9140, pages 1586-1589.
Crossref
Crossref
Joseph Vamecq, Kim Van derpoorten, Jacques H. Poupaert, Jan Balzarini, Erik De Clercq & James P. Stables. (1998) Anticonvulsant phenytoinergic pharmacophores and anti-HIV activity — Preliminary evidence for the dual requirement of the 4-aminophthalimide platform and the N-(1-adamantyl) substitution for antiviral properties. Life Sciences 63:19, pages PL267-PL274.
Crossref
Crossref
J.M. Argilés, N. Carbó & F.J. López-Soriano. (1998) Was tumour necrosis factor-α responsible for the fetal malformations associated with thalidomide in the early 1960s?. Medical Hypotheses 50:4, pages 313-318.
Crossref
Crossref
K Van Derpoorten, J Balzarini, E De Clercq & J.H. Poupaert. (1997) Anti-HIV activity of N-1-adamantyl-4-aminophthalimide. Biomedicine & Pharmacotherapy 51:10, pages 464-468.
Crossref
Crossref
E.J Shannon, Felipe Sandoval & James L. Krahenbuhl. (1997) Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α. Immunopharmacology 36:1, pages 9-15.
Crossref
Crossref
Edward J. Shannon, Melvyn J. Morales & Felipe Sandoval. (1997) Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology 35:3, pages 203-212.
Crossref
Crossref